Huonslab
- Biotech or pharma, therapeutic R&D
Huonslab is dedicated to advancing biologics research and development with a pioneering spirit. Central to its mission is the development of innovative drug delivery technologies such as HyDIZYME (rHuPH20 stand-alone) and HyDIFFUZE (rHuPH20 co-formulation platform, HLB3-002) for universal antibody Sub-Q delivery. With a robust pipeline that includes HLB3-002, a lead drug candidate, and ongoing non-clinical developments in Alzheimer's, Obesity, and Diabetes, Huonslab exemplifies a commitment to addressing the unmet medical needs of patients.
Huonsglobal Co., Ltd., the parent company, is a publicly traded holding company listed on the KOSDAQ since 2006, encompassing 13 subsidiaries specialized in Bio, Pharmaceuticals, and Healthcare with over 2,200 employees worldwide. In 2024, Huonsglobal reported approximately $586 million in sales revenue.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}